Posted by Michael Wonder on 13 Feb 2023
SMC - February 2023 decisions
13 February 2023 - The SMC, which advises on newly-licensed medicines for use by NHSScotland, has today published advice on five new medicines.
Pembrolizumab (Keytruda) was accepted for the treatment of patients with persistent, recurrent, or metastatic cervical cancer. It was considered through SMC’s Patient and Clinician Engagement (PACE) process, which is used for medicines for end of life and rare conditions.
